A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 11 Jun 2017 Results of post hoc analysis assessing time of onset of Eptinezumab efficacy presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 11 Jun 2017 Results of post hoc analysis evaluating changes in HIT-6 scores from baseline to Weeks 4 and 12 (n=588) presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 11 Jun 2017 Primary endpoint (Change in migraine days from baseline to week 12) has not been met for dose levels ALD403 30 mg and 10 mg, according to results presented at the 59th Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top